ITCI vs. GILD
Compare and contrast key facts about Intra-Cellular Therapies, Inc. (ITCI) and Gilead Sciences, Inc. (GILD).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ITCI or GILD.
Correlation
The correlation between ITCI and GILD is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
ITCI vs. GILD - Performance Comparison
Loading data...
Key characteristics
Fundamentals
ITCI:
$14.05B
GILD:
$127.50B
ITCI:
-$0.73
GILD:
$4.76
ITCI:
0.00
GILD:
0.21
ITCI:
20.63
GILD:
4.44
ITCI:
12.23
GILD:
6.65
ITCI:
$535.77M
GILD:
$28.73B
ITCI:
$488.71M
GILD:
$23.07B
ITCI:
-$95.53M
GILD:
$9.89B
Returns By Period
ITCI
N/A
N/A
N/A
N/A
N/A
N/A
N/A
GILD
15.74%
1.55%
21.87%
62.65%
23.18%
11.95%
2.97%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ITCI vs. GILD — Risk-Adjusted Performance Rank
ITCI
GILD
ITCI vs. GILD - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intra-Cellular Therapies, Inc. (ITCI) and Gilead Sciences, Inc. (GILD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
ITCI vs. GILD - Dividend Comparison
ITCI has not paid dividends to shareholders, while GILD's dividend yield for the trailing twelve months is around 2.92%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
ITCI Intra-Cellular Therapies, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GILD Gilead Sciences, Inc. | 2.92% | 3.33% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% |
Drawdowns
ITCI vs. GILD - Drawdown Comparison
Loading data...
Volatility
ITCI vs. GILD - Volatility Comparison
Loading data...
Financials
ITCI vs. GILD - Financials Comparison
This section allows you to compare key financial metrics between Intra-Cellular Therapies, Inc. and Gilead Sciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ITCI vs. GILD - Profitability Comparison
ITCI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Intra-Cellular Therapies, Inc. reported a gross profit of 178.82M and revenue of 199.22M. Therefore, the gross margin over that period was 89.8%.
GILD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported a gross profit of 5.71B and revenue of 6.67B. Therefore, the gross margin over that period was 85.6%.
ITCI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Intra-Cellular Therapies, Inc. reported an operating income of -29.20M and revenue of 199.22M, resulting in an operating margin of -14.7%.
GILD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported an operating income of 3.15B and revenue of 6.67B, resulting in an operating margin of 47.2%.
ITCI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Intra-Cellular Therapies, Inc. reported a net income of -16.89M and revenue of 199.22M, resulting in a net margin of -8.5%.
GILD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported a net income of 1.32B and revenue of 6.67B, resulting in a net margin of 19.7%.